NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Vikram Sinai Talaulikar: New Evidence on Vaginal Estrogen Therapy in Younger Endometrial Cancer Survivors
Vikram Sinai Talaulikar/LinkedIn
Mar 11, 2026, 05:02

Vikram Sinai Talaulikar: New Evidence on Vaginal Estrogen Therapy in Younger Endometrial Cancer Survivors

Vikram Sinai Talaulikar, Associate Specialist in Reproductive Medicine at UCLH and Hon, Associate Specialist in Reproductive Medicine at UCLH and Hon, shared a post on LinkedIn about a paper by Christine D. Hsu et al. published in Menopause:

“An important study from Hsu et al. which evaluated the utilisation of vaginal oestrogen therapy and outcomes associated with its use among younger endometrial cancer survivors. The study is particularly important as the rates of endometrial cancer have been increasing in younger women in different parts of the world.

This is a cohort study using data from the TriNetX database’s US Collaborative Network, which includes electronic health records and insurance claims data from 68 health care organisations. Women 18-51 diagnosed with endometrial cancer between 2005 and 2023 were included. Researchers used 1:1 propensity score matching to create cohorts with and without vaginal oestrogen therapy in the year after their endometrial cancer diagnosis. They estimated hazard ratios (HRs) with 95% CIs for the primary outcome of endometrial cancer recurrence and assessed the risks of negative control outcomes.

1,412 endometrial cancer survivors with vaginal oestrogen therapy and 23,859 without vaginal oestrogen therapy were identified. After propensity score matching, the vaginal ET and non-ET groups included 1,412 individuals each. The mean follow-up times for the vaginal ET and non-ET groups after matching were 4.54 years and 4.07 years respectively. The mean oestrogen therapy treatment duration was 1.88 years.

Endometrial cancer recurrence risk was not increased among those with vaginal oestrogen use (HR, 0.87; 95% CI, 0.60-1.27).

The authors concluded that endometrial cancer survivors with short-term exposure to vaginal oestrogen therapy did not have an elevated risk of endometrial cancer recurrence compared with those without.

Strengths of the study are diverse large cohort, use of negative controls and more than 4 years follow-up. Limitations include – difficulty in stratifying by tumour stage, using proxy outcome for cancer recurrence, inability to assess oestrogen dose response and short-term treatment duration.

Nevertheless, these are reassuring data for women who are endometrial cancer survivors but find themselves making difficult decisions about use of vaginal oestrogen therapy for genitourinary symptoms of menopause after treatment completion.”

Title: Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer

Authors: Christine D. Hsu, Xiaoying Yu, Gwyn Richardson, Yong-Fang Kuo, Fangjian Guo, Victor Adekanmbi, Thao N. Hoang, Pranay Sharma, Abbey B. Berenson

Read the full article.

Vikram Sinai Talaulikar

Stay updated on all scientific advances in the field of fertility with Fertility News.

Abbey B. Berenson Christine D. Hsu Endometrial cancer Fangjian Guo Fertility Fertility News Gwyn Richardson Oestrogen Therapy Pranay Sharma Thao N. Hoang TriNetX Vaginal Oestrogen Therapy Victor Adekanmbi Vikram Sinai Talaulikar Xiaoying Yu Yong-Fang Kuo
NewsFeed